Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors
Phase 1
- Conditions
- Solid Tumor
- Registration Number
- JPRN-jRCT2080221965
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Have solid tumor.
- Have adequate hematologic, hepatic and renal function.
- Have a performance status of higher than or equal to 1 on the Eastern Cooperative Oncology Group scale.
- Able to swallow tablets.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method